Targeting the RAS pathway by mitogen-activated protein kinase inhibitors

被引：13

作者：

Kiessling, Michael K. ^{[1
]}

Rogler, Gerhard ^{[1
]}

机构：

[1] Univ Zurich Hosp, Dept Gastroenterol & Hepatol, Raemistr 100, CH-8091 Zurich, Switzerland

来源：

SWISS MEDICAL WEEKLY | 2015年 / 145卷

关键词：

NRAS mutations; HRAS mutations; MEK inhibitor; ORAL MEK INHIBITOR; SMALL-CELL LUNG; BRAF-MUTANT MELANOMA; PHASE-II; OPEN-LABEL; AZD6244; ARRY-142886; METASTATIC MELANOMA; COMBINATION THERAPY; TUMOR PROGRESSION; DOSE-ESCALATION;

D O I：

10.4414/smw.2015.14207

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Targeting of oncogenic driver mutations with small-molecule inhibitors resulted in powerful treatment options for cancer patients in recent years. The RAS (rat sarcoma) pathway is among the most frequently mutated pathways in human cancer. Whereas targeting mutant Kirsten RAS (KRAS) remains difficult, mutant B rapidly accelerated fibrosarcoma (BRAF) kinase is an established drug target in cancer. Now data show that neuroblastoma RAS (NRAS) and even Harvey RAS (HRAS) mutations could be predictive markers for treatment with mitogen-activated protein kinase (MEK) inhibitors. This review discusses recent preclinical and clinical studies of MEK inhibitors in BRAF and RAS mutant cancer.

引用

页数：9

共 50 条

[31] Mitogen-Activated Protein Kinase Inhibitors Improve Heart Function and Prevent Fibrosis in Cardiomyopathy Caused by Mutation in Lamin A/C Gene [J].

Wu, Wei ;

Muchir, Antoine ;

Shan, Jian ;

Bonne, Gisele ;

Worman, Howard J. .

CIRCULATION, 2011, 123 (01) :53-61

[32] Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma [J].

Carlino, Matteo S. ;

Gowrishankar, Kavitha ;

Saunders, Catherine A. B. ;

Pupo, Gulietta M. ;

Snoyman, Stephanie ;

Zhang, Xu Dong ;

Saw, Robyn ;

Becker, Therese M. ;

Kefford, Richard F. ;

Long, Georgina V. ;

Rizos, Helen .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (07) :1332-1342

[33] The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells [J].

Whipple, Chery A. ;

Boni, Andrea ;

Fisher, Jan L. ;

Hampton, Thomas H. ;

Tsongalis, Gregory J. ;

Mellinger, Diane L. ;

Yan, Shaofeng ;

Tafe, Laura J. ;

Brinckerhoff, Constance E. ;

Turk, Mary J. ;

Mullins, David W. ;

Fadul, Camilo E. ;

Ernstoff, Marc S. .

MELANOMA RESEARCH, 2016, 26 (03) :223-235

[34] Personalizing Therapy Outcomes through Mitogen-Activated Protein Kinase Pathway Inhibition in Non-Small Cell Lung Cancer [J].

Alsharoh, Hasan ;

Chiroi, Paul ;

Isachesku, Ekaterina ;

Tanasa, Radu Andrei ;

Pop, Ovidiu-Laurean ;

Pirlog, Radu ;

Berindan-Neagoe, Ioana .

BIOMEDICINES, 2024, 12 (07)

[35] Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway [J].

Achkar, Iman W. ;

Abdulrahman, Nabeel ;

Al-Sulaiti, Hend ;

Joseph, Jensa Mariam ;

Uddin, Shahab ;

Mraiche, Fatima .

JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16

[36] Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway [J].

Iman W. Achkar ;

Nabeel Abdulrahman ;

Hend Al-Sulaiti ;

Jensa Mariam Joseph ;

Shahab Uddin ;

Fatima Mraiche .

Journal of Translational Medicine, 16

[37] Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors [J].

Boull, Christina ;

Hook, Kristen ;

Moertel, Christopher ;

Maguiness, Sheilagh .

PEDIATRIC DERMATOLOGY, 2017, 34 (01) :90-96

[38] A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma [J].

Thomas, C. L. ;

Mortimer, P. S. ;

Larkin, J. M. ;

Basu, T. N. ;

Gore, M. E. ;

Fearfield, L. .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2016, 41 (03) :267-271

[39] MEK inhibitors: A therapeutic approach to targeting the Ras-MAP kinase pathway in tumors [J].

Sebolt-Leopold, JS .

CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (16) :1907-1914

[40] A novel side effect of mitogen-activated protein kinase inhibitor cobimetinib: Acute corneal decompensation [J].

Asfuroglu, Mahmut ;

Asfuroglu, Yonca .

INDIAN JOURNAL OF OPHTHALMOLOGY, 2019, 67 (12) :2073-+

← 1 2 3 4 5 →